Overview

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Status:
Withdrawn
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Follicular Lymphoma (FL).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Antibodies, Monoclonal
Ofatumumab